DiscGenics

DiscGenics is a private, clinical-stage biopharmaceutical company focused on developing regenerative cell-based therapies to alleviate pain and restore function in patients with degenerative disc diseases. The company’s therapies utilize allogeneic therapeutic progenitor cells derived from intervertebral discs, enabling physicians to treat patients suffering from the debilitating effects of back pain. DiscGenics improves the lives of those weakened by degenerative disc diseases through innovative regenerative treatments. The company is led by a seasoned team of executives from the medical device and biologics industries, practicing clinicians, and successful innovators in the orthopedic, spine, and neurosurgery markets.